Movers and SHAKERS
Baudax Bio (BXRX)
NobleCon 18 Presentation
Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.
Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
NobleCon 18. Gerri Henwood, President and Chief Executive Officer, presented at the conference. The presentation highlighted continued ANJESO growth, reduced cash burn and pipeline progress of the Company’s Neuromuscular Blockers (NMBs) and NMB Reversal Agents. A replay of the presentation can be found here.
ANJESO is growing. Growth has been strong as Baudax Bio continues to win formularies, not only in regional hospitals and ambulatory surgery centers (ASCs), but also integrated delivery networks (IDNs) and national ASC groups. Highly positive clinical experience has helped account penetration ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.